FDA Approves First Drug to Treat Tardive Dyskinesia
The Carlat Psychiatry Report, Volume 15, Number 6, June 2017
Deputy editor, The Carlat Psychiatry Report
Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) for the treatment of tardive dyskinesia (TD), a disabling movement disorder that afflicts 10%–20% of people on chronic antipsychotic medication.